Small Caps Surge on Breakouts, Biotech Validation, and “Real-World” Tech Adoption
Momentum is building across small-cap names this week, with a mix of technical breakouts, clinical validation, and commercialization milestones driving a more constructive tone beneath the surface of the market. $LNAI, $BIAF, $IBRX, $KBLB, $UCAR, $LIDR, $JTAI, $FLYX